AUG 07, 2018 11:00 PM PDT

Can a Myeloid Marker Be Helpful in B-cell Neoplasm Diagnostic Testing?

WRITTEN BY: Mauri Brueggeman

Diagnostic testing for hematologic and other cancers has been a traditional method of evaluating, diagnosing, and providing prognostic information to providers choosing treatment and options for oncology patients.  Molecular diagnostics, in particular, have jumped to the forefront of diagnostic testing to provide not only a diagnosis, but to also evaluate the biomarkers present in particular groups of cells; biomarker identification predicts disease behavior, helps in selection of therapeutic treatment targets and options, assists in stratification of disease, and provides a personalized medicine approach. 

Immunophenotyping has become an invaluable diagnostic tool used by clinicians and hematopathologists to fit cancers into appropriate subgroups based on the biomarkers present on tumor involved cell lines. 

There are a multitude of B-cell neoplasms including multiple myeloma, chronic lymphocytic leukemia, small lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, Burkitt’s lymphoma, Mantle cell lymphoma, and others.  In these cases, because they are lymphoid in origin, it is unexpected to find myeloid markers, however, researchers at Stanford and Oregon Health Sciences in Portland found that CD13, a myeloid marker, is expressed in a subset of lymphomas which can be helpful in differentiating between B-cell neoplasms in the clinical setting.

The group published their findings in the International Journal of Laboratory Hematology, which outlined their analysis of 286 mature B-cell neoplasms after immunophenotyping was completed.  CD13 expression was found in cases of lymphoplasmacytic lymphoma (LPL) (61.5% of cases) and FMC7-positive chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (37% of cases).  Notably, there were no cases of follicular lymphoma that expressed CD13. 

The group concluded that CD13 expression is usually present in LPL and FMC7-positive CLL or SLL and is not found in FL.  Historically, CD13 has not been used to characterize B-cell neoplasm subtypes but could be a useful diagnostic means to aid in neoplasm subtyping and furthering B-cell neoplasm therapeutic targeting.

Sources: International Journal of Laboratory Hematology, Archives of Pathology & Laboratory Medicine, Clinics in Oncology , Modern Pathology 

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
MAR 16, 2020
Cancer
MAR 16, 2020
Aspirin associated with reduced risk of liver cancer
A study published in the New England Journal of Medicine from scientists collaborating from the Karolinska Institutet, i ...
APR 12, 2020
Cancer
APR 12, 2020
Understanding the link between obesity and breast cancer
A researcher from the James Graham Brown Cancer Center at the University of Louisville claims to have figured out the mo ...
APR 27, 2020
Cancer
APR 27, 2020
Talazoparib offers improved quality of life for breast cancer patients
Findings from the Phase III EMBRACA trial have been reported at the American Association for Cancer Research (AACR) annu ...
MAY 09, 2020
Cancer
MAY 09, 2020
Examining a Combination Therapy Against Gastric Cancer
Often when it comes to treatments for cancer, designing or discovering new leads can take years. One of the common pract ...
MAY 23, 2020
Cancer
MAY 23, 2020
Can metformin treat lymphoma?
A popular diabetes medication may be useful in treating cancer, according to new research published recently in Cell Rep ...
MAY 28, 2020
Cancer
MAY 28, 2020
Oncologists need more training on how to deliver bad news
A commentary published earlier this spring in the Journal of Clinical Oncology urges for improved training for medical p ...
Loading Comments...